跳至主要内容
临床试验/IRCT201601213449N20
IRCT201601213449N20已完成3 期

Comparing efficacy and safety of metoclopramide as continuous intravenous infusion and intravenous bolus injection on enteral nutrition tolerance in critically ill patients

Vice Chancellor for Research, Tehran University of Medical Sciences0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 65 years(—)
性别
All

入选标准

  • Critically ill adult patients who are candidate to receive metoclopramide as prokinetic agent due to enteral feeding intolerance (defined as gastric residual volume equal to or greater than 250 ml concomitant with symptoms of nausea, vomiting, and regurgitation or gastric residual volume more than 500 ml during 24 hours of enteral feeding) will be included.
  • Exclusion criteria: Patients with metoclopramide allergy; metoclopramide intolerance; uncontrolled ventricular arrhythmia; extrapyramidal reactions; seizure; head trauma; signs and symptoms of increased intracranial pressure

排除标准

  • 未提供

研究者

发起方
Vice Chancellor for Research, Tehran University of Medical Sciences

相似试验